Lithium Carbonate
Active ingredient
Sold as LITHANE · LITHMAX · CARBOLITH
- Drug class
- -
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 33
- FDA reports (12 mo)
- 559
Overview
Lithium Carbonate is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 17 | February 27, 2026 |
| US United States | FDA | 8 | April 27, 2026 |
| CA Canada | Health Canada | 8 | January 7, 2026 |
GBUnited Kingdom· MHRA
17 products
Uses
The treatment and prophylaxis of mania, manic-depressive illness and recurrent depression, and the treatment of aggressive or self mutilating behaviour.
How to take
USUnited States· FDA
8 products
Uses
1 INDICATIONS AND USAGE Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder: • Treatment of acute manic and mixed episodes in patients 7 years and older [see Clinical Studies ( 14 )] • Maintenance treatment in patients 7 years and older [see Clinical Studies ( 14 )] Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder: • Treatment of acute manic and mixed episodes in patients 7 years and older ( 1 ) • Maintenance treatment in patients 7 years and older ( 1 )
How to take
CACanada· Health Canada
8 products
Uses
CARBOLITH (lithium carbonate) is indicated in: • the treatment of manic episodes of manic-depressive illness. Maintenance therapy has been found to be useful in preventing or diminishing the frequency of subsequent relapses in bipolar manic-depressive patients (with a history of mania).
3 Pediatrics). 4 Geriatrics).
How to take
Drug interactions
Known interactions involving Lithium Carbonate. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 572. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL418710002 · revised May 16, 2025
- [2]FDA DailyMed · 01c4facd-ed79-40… · revised April 27, 2026 [PDF]
- [3]Health Canada (DPD) · 00236683 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.